Barclays
CLDX icon

Barclays’s Celldex Therapeutics CLDX Stock Holding History

Barclays’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,333
Closed -$1.44M – 7087
2014
Q4 		$1.44M Hold
5,333
– – ﹤0.01% 2831
2014
Q3 		$960K Hold
5,333
– – ﹤0.01% 3396
2014
Q2 		$1.28M Hold
5,333
– – ﹤0.01% 3082
2014
Q1 		$1.36M Buy
+5,333
New +$2.04M ﹤0.01% 2918
2013
Q4 		– Sell
-707
Closed -$371K – 7539
2013
Q3 		$371K Buy
+707
New +$242K ﹤0.01% 4433

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CLDX Position: Q2 2026 in Review

Barclays increased its Celldex Therapeutics (CLDX) stake by 8% in Q2 2026, buying an estimated $35.9K and bringing the position to 15,087 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Barclays first reported a position in CLDX in Q2 2013 and has held it in 50 quarters since. The position peaked at $7.04M in Q1 2022. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Barclays held 15,087 shares of Celldex Therapeutics worth $561K as of Q2 2026.
  • Barclays bought 1,112 Celldex Therapeutics shares in Q2 2026, an estimated $35.9K.
  • Celldex Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3145 holding.
  • Barclays first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 50 quarters since.
  • Barclays's Celldex Therapeutics position peaked at $7.04M in Q1 2022.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.